AbbVie Inc (ABBV) Stock Analysis

AbbVie Inc (ABBV) is a publicly traded company in the HEALTHCARE sector. It trades at $215.41, carries a market capitalization of $376.20B, a price-to-earnings ratio of 104.38, a dividend yield of 0.03%. This page summarizes the public market data, fundamentals, and frequently asked questions for ABBV, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - GENERAL

Exchange: NYSE

Key Metrics

Market Sentiment

AbbVie Inc currently has a Bullish sentiment score of 0.20.

About AbbVie Inc

AbbVie Inc is a leading American biopharmaceutical company, established in 2013 from a spin-off of Abbott Laboratories. The company specializes in the research, development, and commercialization of advanced therapies in immunology, oncology, virology, and neuroscience. With a robust pipeline of innovative treatments, AbbVie is committed to addressing some of the world's most challenging health issues and is recognized for its blockbuster immunology drug, Humira. AbbVie continues to strengthe...

GNG Research Analysis

GNG Research scores AbbVie Inc (ABBV) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ABBV.

Frequently Asked Questions

What is ABBV's current dividend yield?

AbbVie Inc (ABBV) has a current dividend yield of 0.03%.

Does ABBV pay dividends?

Yes, AbbVie Inc pays dividends with a current yield of 0.03%.

What is ABBV's P/E ratio?

AbbVie Inc has a price-to-earnings (P/E) ratio of 104.38.

What is ABBV's market cap?

AbbVie Inc (ABBV) has a market capitalization of $376.20B with a current stock price of $215.41.